Aims: To assess efficacy and safety of dulaglutide 1.5 mg combined with insulin, categorized by subgroups of baseline glycated haemoglobin (HbA1c; ≤9% and >9% [≤74.9 and >74.9 mmol/ mol]), age (<65 and ≥65 years), and duration of diabetes (<10 and ≥10 years) at 6 months in patients with type 2 diabetes (T2D).
with basal insulin resulted in significantly greater reductions in HbA1c vs comparators. The HbA1c reduction efficacy was also similar in the pre-specified subgroup analyses vs basal-bolus regimens. 5, 6 The once-weekly GLP-1RA, dulaglutide, has been assessed in 9 phase III clinical trials from the Assessment of Weekly Administration of LY2189265 in Diabetes (AWARD) clinical development programme in >5000 adult patients as monotherapy or as add-on to 1 or 2 oral antihyperglycaemic medications, basal insulin or prandial insulin. Across these studies, the average HbA1c reduction and change in body weight from baseline at the primary endpoint was −0.78% to −1.64% (−8.52 to −17.92 mmol/mol) and −0.87 to −3.03 kg for the 1.5-mg dose and −0.71% to −1.59% (−7.76 to −17.38 mmol/mol) and −2.06 to +0.20 kg for the 0.75-mg dose, respectively. [7] [8] [9] [10] [11] [12] [13] [14] [15] In the United States and the European Union, dulaglutide is indicated for use in combination with both basal or prandial insulin. 16, 17 Dulaglu- 
7,12
Because T2D is a progressive disease where almost 50% of β-cell function is lost before diagnosis, 18 the β-cell-dependent primary mechanism of action of GLP-1RAs can cast doubts in the minds of physicians regarding its efficacy in patients with long-standing disease or in elderly patients who have already resorted to insulin therapy. Despite having the highest prevalence of diabetes of any age group, the proportion of patients aged >65 years is often much smaller than other age groups in clinical trials, which warrants the need for pooled analyses to obtain data for this unique population.
In a recent integrated analysis of 7 AWARD studies, significant improvements in glycaemic control were observed after 6 months of dulaglutide treatment (1.5 mg or 0.75 mg) irrespective of gender, duration of diabetes (<5 years, ≥5 years and <10 years, ≥10 years), or baseline HbA1c (<8.5%, ≥8.5% [<69.4 mmol/mol, ≥69.4 mmol/mol])
in patients with T2D. 19 In another post hoc analysis of 6 AWARD studies, both dulaglutide doses were well tolerated with similar efficacy, irrespective of age (≥65 years, <65 years). 20 In a recent realworld study,~40% of patients initiating dulaglutide were already on insulin therapy. 21 Considering such a large use of the combination of dulaglutide with insulin and its broad indication for use with basal or prandial insulins, this combination needs a more in-depth assessment with regard to elderly patients with long-standing and poorly controlled T2D.
The aim of the present post hoc analysis was to evaluate the efficacy and safety of dulaglutide 1.5 mg combined with basal or prandial insulin in patients with long-standing T2D when categorized by subgroups of baseline HbA1c (≤9%, >9% [≤74.9 mmol/mol, >74.9 mmol/ mol]), age (<65 years, ≥65 years) or duration of diabetes (<10 years, ≥10 years). The main hypothesis was that patients with long-standing T2D treated with once-weekly dulaglutide 1.5 mg combined with prandial or basal insulin significantly reduced HbA1c from baseline, irrespective of age, duration of diabetes or baseline HbA1c. Additionally, taking into account the American Diabetes Association recommendations of less stringent glycaemic goals for older adults with diabetes, glycaemic targets of HbA1c <7% (<53.0 mmol/mol) and <8% (<63.9 mmol/mol) were assessed. 22 2 | RESEARCH DESIGN AND METHODS
| Individual trial design
The present analysis included patients from 2 randomized, phase III clinical trials from the AWARD programme (AWARD-4 and AWARD-9). Individual trial results were previously published. 7, 12 Each trial was designed to evaluate the safety and efficacy of dulaglutide in adults with T2D with a primary endpoint of 26 weeks (AWARD-4) or 28 weeks (AWARD-9). In AWARD-4, the primary objective was to assess the change from baseline in HbA1c with dulaglutide compared with insulin glargine, both when added to prandial insulin lispro three times daily. 7 In AWARD-9, the primary objective was to assess the change from baseline in HbA1c with dulaglutide compared with placebo, both when added to titrated insulin glargine. In AWARD-4, the insulin lispro dose was titrated in each arm based on preprandial and
bedtime glucose values using a lispro algorithm based on Bergenstal et al. 23 In both studies, the insulin glargine dose was titrated to a fasting plasma glucose concentration <100 mg/dL (<5.6 mmol/L). Documented symptomatic hypoglycaemia was defined as plasma glucose 
| Rationale for trial selection
In both AWARD-4 and AWARD-9, the majority of the patients enrolled were receiving basal insulin and metformin. The mean baseline HbA1c for participants in AWARD-4 and AWARD-9 was 8.5%
and 8.4% (69.4 and 68.3 mmol/mol, respectively), the mean age was 58.9 and 60.2 years, and the mean duration of diabetes was 12.8 and 13.0 years, respectively. 7, 12 This similarity in baseline characteristics between the 2 studies made them suitable for pooling to test the hypothesis of this post hoc analysis. Older patients were defined as those aged ≥65 years. 24 Because AWARD-9 assessed only the 1.5-mg dose, only this dose was assessed and pooled in the present analysis.
| Statistical analyses
In this analysis we assessed the efficacy and safety of dulaglutide 3 | RESULTS
| Baseline characteristics
The present analysis included data from 445 patients treated with dulagutide 1.5 mg. These patients were categorized into the following subgroups: baseline HbA1c ≤9% (≤74.9 mmol/mol) (n = 325; 73%); baseline HbA1c >9% (>74.9 mmol/mol) (n = 118; 27%); age <65 years (n = 313; 70%); age ≥65 years (n = 132; 30%); duration of diabetes <10 years (n = 158; 36%); and duration of diabetes ≥10 years Table 1 , as well as the baseline characteristics stratified by subgroup and individual trial for comparators. In AWARD-4, the mean total daily insulin doses at baseline for the dulaglutide and insulin glargine arms were 55.2 IU and 53.9 IU, respectively. 7 In AWARD-9, the mean total daily insulin doses at baseline for the dulaglutide and placebo arms were 40.7 IU and 36.6 IU, respectively. ≤9% and >9% subgroups (≤74.9 and >74.9 mmol/mol subgroups) was 8% (63.9 mmol/mol) and 9.7% (82.5 mmol/mol), respectively. Similar findings were observed in the comparator baseline characteristics by subgroup and by study (Table 1) .
| Pooled dulaglutide 1.5 mg-treated patients glycaemic efficacy by subgroup
At 6 months, dulaglutide 1.5 mg significantly reduced HbA1c and fasting blood glucose (FBG) from baseline in all subgroups (P < .001).
The greatest reduction in HbA1c and FBG was observed in the subgroup of patients with a baseline HbA1c >9% (>74.9 mmol/mol) (least Abbreviations: BMI, body mass index; FBG, fasting blood glucose; HbA1c, glycated haemoglobin. Data are presented as mean AE SD or n (%). Insulin lispro was administered three times daily. For AWARD-9, 150 dulaglutide 1.5 mg-treated patients and 150
placebo-treated patients were included in the present analysis.
HbA1c significantly decreased from baseline with both dulaglutide plus titrated insulin glargine and placebo plus titrated insulin glargine (hereafter, referred to as dulagutide and placebo, respectively) in all subgroups at 6 months (P < .001), with the highest reduction Figure 2B) . Similarly, the total insulin glargine dose in both dulaglutide and comparator arms was higher in the baseline HbA1c >9% (>74.9 mmol/mol) subgroup (Table 2) Changes from baseline in FBG at 6 months according to subgroup and individual study are presented in Table S1 . with the largest increase observed in patients with baseline HbA1c >9% (>74.9 mmol/mol) (mean body weight increase, 3.4 kg [ Figure 3A] ).
In AWARD-9, dulaglutide plus insulin glargine significantly reduced body weight from baseline in all subgroups at 6 months (P ≤ .024), except for patients with a baseline HbA1c >9% (>74.9 mmol/mol) (mean body weight reduction −0.4 kg; mean insulin glargine dose 0.7 U/kg). The largest reduction was observed in patients with baseline HbA1c ≤9% (≤74.9 mmol/mol) (mean body weight reduction −1.7 kg [ Figure 3B] ). Body weight significantly increased from baseline in all subgroups with placebo plus insulin glargine at 6 months (P ≤ .047). Similar to AWARD-4, the largest increase was observed in patients with baseline HbA1c >9% (>74.9 mmol/mol) (mean body weight increase 1.3 kg).
3.5 | Safety
| Hypoglycaemia
The incidence and rate of documented symptomatic hypoglycaemia and number of severe hypoglycaemic events by individual study are shown in Table S2 . Overall in AWARD-4, the rate of documented symptomatic hypoglycaemia was high in both the dulaglutide and comparator arms, with numerically higher rates in the comparator arm 25 (Table S2 ). The rate of documented symptomatic hypoglycaemia with dulaglutide plus insulin lispro was similar in all subgroups, except for patients with a duration of diabetes ≥10 years who had a numerically higher rate compared with patients with a duration <10 years (35.8 vs 25.4 events/patient/y). In AWARD-9, the rate of documented symptomatic hypoglycaemia with dulaglutide 1.5 mg was generally similar within subgroups. The highest rate of documented symptomatic hypoglycaemia was observed in the subgroup with a baseline HbA1c >9% (>74.9 mmol/mol) (5.7 events/patient/y). (Table S2) , while there was only 1 event of severe hypoglycaemia in dulaglutide-treated patients in AWARD-9.
| Other adverse events
The complete safety profile for each study was previously reported. 7, 12 The most common adverse events in both studies were gastrointestinal in nature (including nausea, diarrhoea and vomiting) and were mild to moderate in severity and transient (data not shown).
| DISCUSSION
In the present analysis, dulaglutide 1.5 mg combined with insulin in patients with T2D resulted in significant and clinically meaningful HbA1c reductions irrespective of baseline HbA1c, age and duration of diabetes. Results were consistent between both pooled and individual study analyses.
The greatest HbA1c reduction was observed in dulaglutidetreated patients with baseline HbA1c >9% (>74.9 mmol/mol) in the pooled data and by individual study. In a broader analysis assessing key predictive factors that impact glycaemic efficacy with dulaglutide, baseline HbA1c was the most important predictor, which is consistent with the present results. 26 In studies assessing other long-acting GLP-1RAs, such as semaglutide, albiglutide and liraglutide added to basal insulin, a larger HbA1c reduction was also observed in patients with higher baseline HbA1c. [27] [28] [29] In a post hoc analysis of SUSTAIN-5 that assessed semaglutide 0.5 mg and 1.0 mg added to basal insulin, a reduction in HbA1c of −2.2% and −2.5% (−24.0 and −27.3 mmol/ mol, respectively) was observed in the subgroup with baseline HbA1c >9% (>74.9 mmol/mol), with 62% and 83% of patients achieving HbA1c target <8% (<63.9 mmol/mol), respectively. 29 Taking into account that SUSTAIN-5 had differences in study design and basal insulin titration schemes, these results mostly align with our subgroup analysis for baseline HbA1c >9% (>74.9 mmol/mol) in AWARD-9.
Furthermore, fixed-ratio combinations of basal insulin and liraglutide or lixisenatide (ie, IDegLira and iGlarLixi) have also led to significant and safety irrespective of age. 20 Similar results were observed in other post hoc analyses assessing safety and efficacy of other GLP1RAs of fixed-dose combination by age. [32] [33] [34] Over time, glycaemic control decreases in patients with T2D
because of the chronic and progressive nature of the disease. 35 In the present analysis, clinically meaningful and similar HbA1c reductions were observed in both duration of diabetes subgroups (<10 years, ≥10 years) in the pooled dulaglutide analysis. This was also consistent for individual studies. In a previous post hoc analysis, dulaglutide showed significant HbA1c reductions irrespective of baseline β-cell function measured by HOMA2-%β. 36 A recent study that assessed dulaglutide combined with insulin lispro in patients with chronic kidney disease (stages 3 and 4), and a mean duration of diabetes of 17 years showed similar efficacy to that in the basal-bolus comparator arm. 15 These data are supportive of the glucose-lowering ability of dulaglutide, irrespective of the duration of diabetes when added to the insulin regimen. Similarly, patients with a mean duration of diabetes of 13 years had significant improvements in glycaemic control in long-term cardiovascular outcome trials assessing the efficacy of long-acting GLP-1RAs, such as liraglutide and semaglutide.
1,2
Treatment with albiglutide resulted in similar glycaemic efficacy when assessed among categories of duration of diabetes of <5 years, ≥5 years, <10 years and ≥10 years, overall and in insulin studies. 37 Additionally, treatment with the fixed-ratio combination of lixisenatide plus insulin glargine resulted in a similar HbA1c effect in patients with a duration of diabetes <10 years and ≥10 years. 30 Body weight data were not pooled because of the variable effects basal and prandial insulin have on weight and, therefore, were assessed only by individual study. At 6 months, dulaglutide decreased body weight in all subgroups except for a slight weight gain observed in patients with baseline HbA1c >9.0% (>74.9 mmol/mol) from AWARD-4, in which dulaglutide was combined with high doses of insulin lispro three times daily. This subgroup specifically used the highest dose of insulin lispro, which may have prevented the reduction in weight associated with dulaglutide treatment. However, treatment differences in weight changes given the increase in body weight in the comparator arm were statistically and clinically significant. Similarly, in AWARD-9 at 6 months, dulaglutide decreased body weight in all subgroups except for patients with baseline HbA1c >9.0% (>74.9 mmol/mol); however, treatment difference was significant vs the comparator. This subgroup was also receiving the highest dose of insulin, reflecting the impact of concomitant therapy on weight changes. Additionally, higher doses of concomitant insulin therapy may increase the risk of hypoglycaemia, as was the case in AWARD-4. Still, patients receiving dulaglutide had numerically lower rates of hypoglycaemia compared with patients on a basal-bolus regimen.
Several limitations should be considered when interpreting these results. First, this was a post hoc analysis with no adjustments for multiple testing and with imbalanced sample sizes in different subgroups. Although the cut-off of ≥65 years was used for the elderly category, the percentage of patients aged ≥75 years was small. In addition, patients were on different types of insulin (either basal or prandial) with different titration schemes. Moreover, the durations of the studies in the present analysis were limited to 6 months, which may not represent the effects of long-term use of dulaglutide. These data are intended to help clinicians take an individualized treatment approach for patients with T2D, providing additional insight into adding dulaglutide therapy in patients already treated with insulin.
In conclusion, dulaglutide 1.5 mg combined with basal or prandial insulin was found to be an efficacious option for elderly patients with long-standing poorly controlled diabetes, and the overall safety pro- 
